Acrivon Therapeutics
IPOPrecision oncology powered by proteomics
- Headquarters
- Watertown, Massachusetts
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- acrivon.com
- Total Funding
- $230.0M
- Last Round
- $130.0M Venture RoundApr 2024
- Rounds
- 2
- Type
- Public
About
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines utilizing its proprietary Acrivon Precision Predictive Proteomics (AP3) platform. The AP3 platform enables unprecedented patient selection by profiling the activity of key cancer-driving proteins at the individual tumor level, identifying which patients are most likely to respond to a given targeted therapy. Headquartered in Watertown, Massachusetts, Acrivon is advancing a pipeline of precision oncology drug candidates, including ACR-368, a CHK1/2 inhibitor being evaluated in endometrial and ovarian cancers.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Biopharmaceutical services company
Specialty pharmaceutical company
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.